Oral Bisphosphonate-related Osteonecrosis of the Jaws: Clinical Characteristics of a Series of 20 Cases in Spain

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2012 May 3

PMID 22549688

Citations 15

Authors

Marcio Diniz-Freitas

Jose-Luis Lopez-Cedrun

Jacinto Fernandez-Sanroman

Abel Garcia-Garcia

Javier Fernandez-Feijoo

Pedro Diz-Dios

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain.

Study Design: A retrospective multicentre study was undertaken in 3 hospitals in an area with a radius less than 100 km in the Autonomous Community of Galicia (Spain). The medical records were reviewed and an oral examination was performed of patients diagnosed with oral bisphosphonate-related ONJ in the previous 3 years.

Results: We detected 20 cases of ONJ (24 lesions) related to oral bisphosphonates (alendronate [16 patients] and ibandronate [4 patients]), which were mainly administered as treatment for osteoporosis (17 patients). The mean interval between initiation of treatment and confirmation of a diagnosis of ONJ was 66±43 months (range, 6-132 months); in 7 patients (35%) the interval was less than 36 months. The past history revealed hypertension in 13 cases (65%) and diabetes in 4 (20%); 7 patients (35%) were on corticosteroid treatment. Oral surgery had been previously performed in 13 patients (65%) and the remaining 7 patients (35%) had removable dental prostheses. The lesions most frequently affected the posterior mandible (62.5%). The majority of the lesions (75%) were classified as stage 2, although lesions were identified in all established clinical stages (including 2 stage 0 lesions).

Conclusion: In conclusion, in the present series, ONJ induced by oral bisphosphonates typically develops in women around 70 years of age, taking alendronate, that underwent oral surgery. Most lesions are located in the posterior mandible and are classified as stage 2 at diagnosis. Some patients presented no known risk factors, suggesting that there may be risk factors still to be identified. There are well-defined patterns of clinical presentation that can facilitate early diagnosis of ONJ.

Citing Articles

A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials.

Hanna R, Miron I, Dalvi S, Arany P, Bensadoun R, Benedicenti S Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204116 PMC: 11357434. DOI: 10.3390/ph17081011.

Dentists' Awareness of Medication-Related Osteonecrosis of the Jaw (Risk Factors, Drugs, and Prevention) in the Republic of Croatia.

Bival S, Simovic L, Blazun A, Bergman L, Vrazic D, Granic M Acta Stomatol Croat. 2023; 57(2):121-132.

PMID: 37427357 PMC: 10323933. DOI: 10.15644/asc57/2/3.

Mirelli C, Marino S, Bovio A, Pederielli S, DallAgnola C, Gianni A Dent J (Basel). 2022; 10(5).

PMID: 35621542 PMC: 9139814. DOI: 10.3390/dj10050089.

Therapeutic Approach in the Treatment of Medication-Related Osteonecrosis of the Jaw: Case Series of 3 Patients and State of the Art on Surgical Strategies.

Vettori E, Pipinato G, Bussani R, Costantinides F, Nicolin V, Bevilacqua L J Oral Maxillofac Res. 2021; 12(2):e6.

PMID: 34377383 PMC: 8326883. DOI: 10.5037/jomr.2021.12206.

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review.

Sacco R, Woolley J, Yates J, Calasans-Maia M, Akintola O, Patel V J Res Med Sci. 2021; 26:23.

PMID: 34221052 PMC: 8240545. DOI: 10.4103/jrms.JRMS_794_20.

References

Neto N, Bastos A, Chierici-Marcantonio R, Marcantonio Jr E . Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws?. Med Hypotheses. 2011; 77(5):905-11. DOI: 10.1016/j.mehy.2011.08.008. View

Sambrook P, Cooper C . Osteoporosis. Lancet. 2006; 367(9527):2010-8. DOI: 10.1016/S0140-6736(06)68891-0. View

Palaska P, Cartsos V, Zavras A . Bisphosphonates and time to osteonecrosis development. Oncologist. 2009; 14(11):1154-66. DOI: 10.1634/theoncologist.2009-0115. View

Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P . Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2010; 40(3):277-84. DOI: 10.1016/j.ijom.2010.11.002. View

Tanko L, Christiansen C, Cox D, Geiger M, McNabb M, Cummings S . Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20(11):1912-20. DOI: 10.1359/JBMR.050711. View

Grana J, Mahia I, Meizoso M, Vazquez T . Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (Pathological fracture associated with ONJ and BP use for osteoporosis). Clin Exp Rheumatol. 2008; 26(2):384-5. View

Favia G, Pilolli G, Maiorano E . Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol. 2009; 36(12):2780-7. DOI: 10.3899/jrheum.090455. View

Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S . Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007; 18(10):1363-70. DOI: 10.1007/s00198-007-0384-2. View

Valdes S, Rojo-Martinez G, Soriguer F . [Evolution of prevalence of type 2 diabetes in adult Spanish population]. Med Clin (Barc). 2007; 129(9):352-5. DOI: 10.1157/13109554. View

10.

. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76. DOI: 10.1016/j.joms.2006.11.003. View

11.

Otto S, Abu-Id M, Fedele S, Warnke P, Becker S, Kolk A . Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. J Craniomaxillofac Surg. 2010; 39(4):272-7. DOI: 10.1016/j.jcms.2010.05.009. View

12.

Kunchur R, Goss A . The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J. 2009; 53(4):354-7. DOI: 10.1111/j.1834-7819.2008.00078.x. View

13.

Sonis S, Watkins B, Lyng G, Lerman M, Anderson K . Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2008; 45(2):164-72. DOI: 10.1016/j.oraloncology.2008.04.013. View

14.

Hong J, Nam W, Cha I, Chung S, Choi H, Kim K . Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int. 2009; 21(5):847-53. DOI: 10.1007/s00198-009-1024-9. View

15.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

16.

Edwards B, Hellstein J, Jacobsen P, Kaltman S, Mariotti A, Migliorati C . Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008; 139(12):1674-7. DOI: 10.14219/jada.archive.2008.0110. View

17.

Bagan J, Murillo J, Jimenez Y, Poveda R, Milian M, Sanchis J . Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005; 34(2):120-3. DOI: 10.1111/j.1600-0714.2004.00269.x. View

18.

Chiu C, Chiang W, Chuang C, Chang S . Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis. J Oral Maxillofac Surg. 2010; 68(5):1055-63. DOI: 10.1016/j.joms.2009.12.030. View

19.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

20.

Lazarovici T, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N . Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg. 2009; 67(4):850-5. DOI: 10.1016/j.joms.2008.11.015. View